Sign In
Buy PCSA
$2.15
+0.110 (+5.39%)
At Close: Jul 31, 2026
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
08:00am, Friday, 13'th Jun 2025
HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announce
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
09:00am, Friday, 30'th May 2025
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with im
Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025
08:00am, Tuesday, 15'th Apr 2025
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next genera
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
08:30am, Tuesday, 18'th Mar 2025
HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generat
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
08:00am, Friday, 07'th Feb 2025
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generati
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
05:17pm, Thursday, 30'th Jan 2025
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the ne
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
08:30pm, Monday, 27'th Jan 2025
HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the ne
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
04:05pm, Wednesday, 02'nd Oct 2024
HANOVER, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generati
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
08:00am, Tuesday, 03'rd Sep 2024
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during
Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?
11:08am, Tuesday, 30'th Jul 2024
Processa Pharmaceuticals (NASDAQ: PCSA ) stock is rising higher on Tuesday after the company posted an update from the Food and Drug Administration (FDA). The FDA has cleared Processa Pharmaceuticals
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (P
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
08:00am, Monday, 06'th May 2024
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the ne
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
08:00am, Tuesday, 30'th Apr 2024
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clini
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
08:15am, Thursday, 28'th Mar 2024
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the n
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
08:15am, Monday, 25'th Mar 2024
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the n
